AUA 2019: Oncological Effectiveness of Image Guided Thermal Ablation for Recurrent Renal Cell Carcinoma after Ipsilateral Partial Nephrectomy: Tertiary Cancer Center Experience

Chicago, IL (UroToday.com) Renal cell carcinoma is often treated with surgery. Image-guided thermal ablation is a novel technique and surgical alternative that is used to destroy tumors through the application of intense heat.

Dr. Mohamed Abdelsalam and his co-authors sought out to examine image-guided thermal ablation of recurrent renal cell carcinoma (RCC) post-ipsilateral partial nephrectomy, and its oncologic benefits.

The renal ablation database of the institution was utilized throughout the institution within a 13-year time period, in search of patients that had a thermal ablation for recurrent RCC after partial nephrectomy, under certain inclusion criteria (demographics, tumor size, procedure details, complications, etc.).

The study found that out of 46 qualifying cases, 12% of the cohort developed grade III complications according to Clavien-Dino classification, 1 being a urethral injury, 3 patients being a blood clot and ureteral injuries. Abdelsalam presented a case included in the study, that illustrated an initial 1.3cm lesion, it's imaging during biopsy and RFA, and a 9 year follow up displaying no evidence of the lesion.

Abdelsalam concludes his presentation reinstating that image-guided thermal ablation is an effective treatment for recurrent renal cell carcinoma post-ipsilateral partial nephrectomy. He also states that guided and longitudinal imaging shows positive oncologic outcomes.


Presented by: Mohamed E. Abdelsalam, MD, Department of Interventional Radiology, University of Texas MD Anderson Cancer Center

Written by: Aleesa Chavez, (Department of Urology, University of California, Irvine) at the American Urological Association's 2019 Annual Meeting (AUA 2019), May 3 – 6, 2019 in Chicago, Illinois
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe